EUVIMEDEUVIMED entdecken
Crossref

Engineering Dual‐Responsive Prodrug‐MOFs as Immunogenic Cell Death Initiator for Enhancing Cancer Immunotherapy

Xiaochun Hu, Ruihao Li, Jie Liu, Kang Fang, Chunyan Dong, Shuo Shi iD

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202302333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Xiaochun Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Chemical Assessment and Sustainability, School of Chemical Science and Engineering, Department of Comprehensive Cancer The…. Hauptthemen laut MEDLINE: Prodrugs, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Natural Science Foundation of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, the anticancer effects of disulfiram, a clinical drug for anti‐alcoholism, are confirmed. However, several defects limit the clinical translation of disulfiram obviously, such as Cu(II)‐dependent anticancer activity, instability, and non‐selectivity for cancer cells. Herein, a phosphate and hydrogen peroxide dual‐responsive nanoplatform (PCu‐HA‐DQ) is reported, which is constructed by encapsulating disulfiram prodrug (DQ) and modifying hyaluronic acid (HA) on copper doping metal–organic frameworks (PCu MOFs). PCu‐HA‐DQ is expected to accumulate in tumor by targeting CD‐44 receptors and enable guidance with magnetic resonance imaging. Inside the tumor, Cu(DTC) 2 will be generated in situ based on a dual‐responsive reaction. In detail, the high concentration of phosphate can induce the release of DQ, after that, the intracellular hydrogen peroxide will further mediate the generation of Cu(DTC) 2 . In vitro and in vivo results indicate PCu‐HA‐DQ can induce the apoptosis as well as immunogenic cell death (ICD) of tumor cells distinctly, leading to enhanced immune checkpoint inhibitor (ICI) efficacy by combining the anti‐programmed death‐1 antibody. This work provides a portable strategy to construct a dual‐responsive nanoplatform integrating tumor‐targeted ability and multi‐therapy, and the designed nanoplatform is also an ICD inducer, which presents a prospect for boosting systemic antitumor immunity and ICI efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNeoplasmsNanoparticlesHumansDisulfiramImmunogenic Cell DeathCopperHydrogen PeroxideImmunotherapyPhosphatesCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

Russell mechanismimmune checkpoint inhibitorimmunogenic cell deathmetal-organic frameworkstumor microenvironment

Substanzen

ProdrugsDisulfiramCopperHydrogen PeroxidePhosphates

Autor:innen und Institutionen

  • Shanghai Key Laboratory of Chemical Assessment and Sustainability, School of Chemical Science and Engineering, Department of Comprehensive Cancer Therapy, Shanghai East Hospital, School of Medicine, Tongji University, S…
  • School of Medicine, Shanghai University, Shanghai, 200444, P. R. China.

ORCID-Profile: Shuo Shi

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities
  • Natural Science Foundation of Shanghai
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Hu, X., Li, R., Liu, J., Fang, K., Dong, C., & Shi, S. (2024). Engineering Dual‐Responsive Prodrug‐MOFs as Immunogenic Cell Death Initiator for Enhancing Cancer Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202302333

Vancouver

Hu X, Li R, Liu J, Fang K, Dong C, Shi S. Engineering Dual‐Responsive Prodrug‐MOFs as Immunogenic Cell Death Initiator for Enhancing Cancer Immunotherapy. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202302333

BibTeX
@article{Hu2024,
  author = {Hu, Xiaochun and Li, Ruihao and Liu, Jie and Fang, Kang and Dong, Chunyan and Shi, Shuo},
  title = {Engineering Dual‐Responsive Prodrug‐MOFs as Immunogenic Cell Death Initiator for Enhancing Cancer Immunotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202302333}
}
Kostenlos starten →